1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, A8
Financial Results, Press Release
CARDAMYST™: First FDA-Approved, Self-Administered Treatment for PSVT
Other Events
Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency
Receives FDA Approval of CARDAMYST™
Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants
FY 2025
Q3
Q2
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Amended Statement of Changes in Beneficial Ownership
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload